Amneal Pharmaceuticals Stock News

Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Tony DiMeo – Head-Investor Relations Chirag Patel – President and Co-Chief Ex

Amneal (AMRX) delivered earnings and revenue surprises of 0% and 0.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals shares have fallen in value from $24 to $4 since September 2018.

Amneal Pharmaceuticals and Kashiv Biosciences have announced that their RELEUKO (filgrastim-ayow) biosimilar recently received FDA approval, making it the third filgrastim biosimilar approved…

Amneal Pharmaceuticals <> stock declined following its mixed Q4 results and and non-GAAP EPS guidance below estimates. Q4 revenue rose +5.27% Y/Y to $536.9M. The increase was…

Amneal Pharmaceuticals Inc (NYSE: AMRX ) reports Q4 revenue of $537 million , an increase of 5% Y/Y, marginally missing the consensus of $537.35 million. The increase was driven by Generic product launches and growth in Specialty products Rytary and Unithroid, partially offset by price erosion. Adjusted EPS was $0.18, below the consensus of $0.20, and better than $0.14 posted a year ago. Adjusted EBITDA increased 18% to … Full story available on Benzinga.com

Amneal Pharmaceuticals (AMRX) CEO, Chirag Patel on Q4 2021 Results - Earnings Call Transcript

Amneal Pharmaceuticals press release (AMRX): Q4 Non-GAAP EPS of $0.18 misses by $0.02.Revenue of $537M (+5.3% Y/Y) beats by $3.59M. Provides 2022 Financial Guidance of $2.15 to…

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the fourth quarter and full year ended December 31, 2021. “2021 was a transformational year for Amneal as we delivered strong financial results, including 18 percent adjusted EBITDA growth, and advanced our evolution into a diversified biopharmaceutical company. We continued to deepen our robust R&D pipeline and added compelling assets in key growth areas

Amneal (AMRX) delivered earnings and revenue surprises of -5.26% and 1.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • SIGNA Sports United (NYSE: SSU ) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. • IsoPlexis (NASDAQ: ISO ) is likely to report quarterly loss at $0.68 per share on revenue of $5.45 million. • Innoviz Technologies (NASDAQ: INVZ ) is likely to report quarterly loss at $0.18 per share on revenue of $2.93 million. • International Seaways (NYSE: INSW ) is expected to report quarterly loss at $0.36 per share on revenue of $102.60 million. • Dine Brands Global (NYSE: DIN ) is estimated to report quarterly earnings at $1.27 per share on revenue of $236.67 million. • Dollar Tree (NASDAQ: DLTR ) is expected to report quarterly earnings at $1.77 per share on revenue of $7.12 billion. • Valens Semiconductor (NYSE: VLN ) is projected to report quarterly loss at $0.06 per share on revenue of $20.04 million. • Sterling Check (NASDAQ: STER ) is projected to report quarterly earnings at $0.17 per share on revenue of $152.50 million.

Amneal Pharmaceuticals (AMRX) said the U.S. FDA approved its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen.The product will be marketed…

Amneal Pharmaceuticals (NYSE:AMRX) is scheduled to announce Q4 earnings results on Wednesday, Mar. 2, before market open.Consensus EPS estimate is $0.20 (+42.9% Y/Y)